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Experimental  allergic encephalomyelitis (EAE) l is induced in  Lewis rats by a 
single injection of guinea pig spinal cord homogenate emulsified with complete 
Freund's adjuvant (GPSCH-CFA). The  typical symptoms are weight loss of 5- 
10% beginning on day 8 or 9, followed by moderate to severe hind limb paralysis 
commencing on days 12-14 and lasting for an average of 8 d. Recovery is always 
complete  by day  28.  Some  aspects  of EAE  are  considered  to  mimic  human 
multiple sclerosis. In both diseases (1), inflammatory lesions are found predomi- 
nantly  in  the  white  matter  of the  brain  and  spinal  cord,  the cellular  infiltrate 
consisting  principally  of  T  lymphocytes  of  the  delayed-type  hypersensitivity 
(DTH)/helper  subset and  monocyte/macrophages  (2,  3).  The  DTH/helper  T 
cells  tend  to  be  located  at  the  periphery  of the  lesion,  extending  into  the 
surrounding  normal  tissue (4,  5).  This  distribution  pattern,  together  with  the 
fact that  EAE can  be transferred  to naive animals  by sensitized  T  cells of the 
DTH/helper  type (6-8),  suggests that  such T  iymphocytes initiate  the  disease 
process. 
The initial  invasion of T  cells in the central  nervous system on day 5 or 6 is 
followed by the appearance of macrophages (4): macrophages are essential both 
for the induction (9) and pathological effects (10) of EAE, and activated macro- 
phages are  able  to destory myelin  (11).  Activated  macrophages  liberate  many 
factors, including hydrogen peroxide and superoxide (12),  which may react in 
the presence of free (non-heme)  iron to give the highly toxic hydroxyl radical 
(. OH) by a series of reactions summarized by the overall equation (13): 
H202+O2 ~  iron catalyzed  ~O2+  .OH+OH-. 
The generation of •  OH in a lipid-rich environment, such as myelin, may cause 
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extensive damage by producing a  chain reaction of lipid peroxidation,  macro- 
phage chemotaxis, and free radical generation. In addition, the free iron neces- 
sary to catalyze the production of hydroxyl radicals may be available in lesions 
of EAE and multiple sclerosis as a  result of blood extravasation, hemolysis, and 
subsequent hemoglobin breakdown. It is thus possible that free radical-induced 
tissue  damage  could  contribute  significantly to  the  pathology  of the  disease 
process (14). 
With this mechanism in mind, we have examined the effect of desferrioxamine 
B mesylate (DFOM) on the inflammatory lesions of EAE. As a  chelating agent 
with a  particularly high affinity for Fe  s+,  DFOM  will compete successfully for 
free or loosely bound iron, which is then excreted. More tightly bound iron such 
as that in hemoglobin is not affected (15).  We report here that treatment with 
DFOM dramatically suppresses both the clinical symptoms and pathology of EAE 
in  Lewis  rats.  The  improved  clinical  status  of the  DFOM-treated  animals  is 
reflected in the diminished severity of inflammatory lesions in the central nervous 
system, and in reduced DTH T  cell responses measured in vitro. The fact that 
DFOM has seen extensive clinical use, with few side effects, raises the possibility 
that treatment protocols involving iron chelation may be beneficial as a relatively 
mild immunosuppressive  procedure  for  the  management of multiple sclerosis 
and other inflammatory/degenerative processes. 
Materials and Methods 
Rats.  Female Lewis/JC rats were bred at the John Curtin School of Medical Research. 
They were used at 8-10 wk of age and weighed ~ 120-150 g. 
Induction  of EAE.  A  20%  suspension  of guinea  pig  spinal  cord  homogenate was 
emulsified in an equal volume of Freund's incomplete adjuvant (Commonwealth Serum 
Laboratories, Melbourne, Australia) containing 4 mg/ml Mycobacterium butyricum (Difco 
Laboratories, Inc.,  Detroit MI).  This inoculum is designated GPSCH-CFA.  Rats were 
injected with 0.2 ml, divided between the footpads of all four feet. 
Clinical Assessment.  Clinical symptoms were assessed on a scale of 0-5, as follows: 0, 
asymptomatic; 1, weight loss, flaccid tail;  2, ataxia, slow righting reflex; 3, paraparesis, 
incontinence; 4, paraplegia or quadriplegia, no voluntary limb movement; 5, moribund 
or death. 
Histology.  Brains and spinal cords were fixed in formal saline, embedded in paraffin, 
and stained with hemotoxylin and eosin or with periodic acid-Schiff. 
Administration of Desferrioxamine.  Desferrioxamine B mesylate (Desferal)  was kindly 
donated by Ciba-Geigy Australia, Ltd., Lane Cove, New South Wales.  Since Desferal is 
excreted rapidly in vivo (16), it was administered via an osmotic pump (type 2ML 1; ALZA 
Corp., Palo Alto, CA) that was implanted subcutaneously. The drug was reconstituted in 
water at 250 mg]ml, and the pumps, (with a 2-ml capacity),  delivered ~70 mg Desferal 
per rat per day over a period of 7 d, at a continous rate of 10 t~l/h. The levels of DFOM 
(17) in the plasma of one rat measured on days 1, 5, and 8 after implantation of the pump 
were 12, 15, and 10 ~g/#l, respectively. In all experiments, EAE controls inoculated with 
GPSCH-CFA were sham operated. At the end of the treatment, the pumps were removed 
and the rats were observed for a further 14 d. For in vitro studies, saturated DFOM was 
prepared by mixing equimolar amounts of DFOM with FeCI3, since DFOM binds Fe  a+ in 
a  1:1 ratio. 
Preparation of Cell Suspensions.  Peritoneal exudate ceils (PEC) were induced by intra- 
peritoneal injection of thioglycollate medium (Difco Laboratories, Inc.) 3 d before sam- 
pling. The cells were obtained from anesthetized animals by washing out the peritoneal 
cavity with 20 ml cold Hanks' balanced salt solution. This allowed repeated sampling of 
individual rats.  Since the presence  of erythrocytes may result in false  positives  in the 1534  ROLE  OF  IRON  IN  AUTOIMMUNITY 
procoagulant assay,  erythrocytes were removed from the PEC preparations by layering 
on Isopaque-Ficoll (Pharmacia, Uppsala, Sweden). <1% red cells remained after separa- 
tion. Lymph node cells (LNC) were prepared by disaggregation of popliteal lymph nodes 
into RPMI. The cells were washed, filtered through nylon gauze (20 #m; Simons Ltd., 
Sydney), and resuspended in RPMI  1640 (Gibco Laboratories, Grand Island, NY) con- 
taining 5% heat-inactivated fetal calf serum and antibiotics. 
Macrophage Procoagulant Assay (MPCA).  The MPCA assay (18, 19) depends on specif- 
ically  sensitized T  cells  recognizing antigen presented on appropriate stimulator cells. 
These lymphocytes then release lymphokine(s), which causes the production of procoag- 
ulant on the surface of the macrophages. It is this procoagulant that is measured by the 
capacity to reduce the clotting time of plasma.  All media used in this assay  were first 
filtered through a  Zetapor filter (American Machine and Foundry Co. (Australia) Pry. 
Ltd., Chatswood, Australia) to remove endotoxin. Peritoneal cells (2 × 106) were incubated 
with or without myelin basic protein (MBP),  10 ~g/ml in 0.5 ml RPMI containing 5% 
heat-inactivated fetal calf serum. After 16 h incubation at 37 °C, 5% CO2, the cells were 
washed twice and resuspended in 200 #1 of Hanks' balanced salt solution. 100 t~l of cell 
suspension was mixed with an equal volume of rat plasma (prepared as described by Geczy 
and Meyer [19]) and, upon addition of 100 #1 of CaCI2 (0.03 M), the clotting time (CT) 
was estimated using a BBL fibrinometer (Becton, Dickinson & Co., Sunnyvale, CA). The 
percent reduction in clotting time (RCT) was estimated as follows: Percent RCT =  [(CT 
without antigen) -  (CT with antigen)/(CT without antigen)] ×  100.  Lymph node cells 
were incubated with MBP (10 #g/ml) at 2 ×  106/ml in RPMI, 5% heat-inactivated fetal 
calf serum (HIFCS), plus  10  -4  M  2-mercaptoethanol. After 72  h, the lymphokine-rich 
supernatant was removed and diluted 1:5. A 0.3-ml aliquot was then incubated for 16 h 
with 4 ×  105 PU5 cells, a continuous macrophage line that produces procoagulant factor 
upon stimulation with lymphokine (18), and the cells were assayed as above. 
Characterization of Effectors.  The lymphocytes that respond in the procoagulant assay 
were characterized using monoclonal antibodies specific for rat T  cell subsets.  The W3/ 
25  (helper/DTH) and  OX8  (cytotoxic) monoclones were kindly supplied by Dr.  Alan 
Williams,  Sir William Dunn School of Pathology, Oxford. LNC were incubated (30 min 
at 4°C) with  these monoclonal antibodies, washed three times in  PBS, incubated with 
fluorescein-conjugated goat anti-mouse IgG (CSL, Melbourne), and washed again three 
times in PBS. They were then separated on a fluorescence-activated  cell sorter (FACS IV; 
B-D FACS Systems, Sunnyvale, CA) using a  488-#m excitation wavelength, and, after 
culture for 72 h with MBP, supernates were assayed for procoagulant activity using the 
PU5 cell line. 
Measurement oft Cell Proliferation by Thymidine Uptake.  LNC were suspended in RPMI, 
5% HIFCS, plus PSN, and incubated at 37°C in 5% CO2 in air for 24 h, in 96-well Linbro 
trays at 2 ×  10  ~ cells/0.2-ml well. Reagents were added at the following concentrations: 
Con A,  1 #g/ml; MBP, 5 #g/ml; DFOM,  10 #g/ml; FeCI3, 0.1  mM. After 24 h, 0.2 #Ci 
[3H]thymidine in 24 #1 was added to each well and incubated at 37°C in 5% CO2 for 5 h. 
Cells were harvested onto filter papers using a Titertek cell harvester, transferred to vials 
containing 5 ml scintillation fluid (xylene/PPO), and counted in a Tri-carb liquid scintil- 
lation spectrometer (Packard Instrument Co., Downers Grove, IL) 
Results 
Effect on Clinical EAE.  Treatment of GPSCH-CFA-sensitized rats with DFOM 
before  the  onset  of  symptoms  either  completely  abrogated  the  weight  loss 
associated with clinical EAE (days 0-7, Fig. 1 a), or greatly reduced the magnitude 
of such  weight  loss (days 8-15,  Fig.  1 b).  The same general effect was seen in 
rats given the drug from day 11 to 18 (Fig.  1 c). Also, clinically affected rats that 
were treated on days 14-21 regained weight more rapidly than did the untreated 
controls (Fig.  1 d). Administration of DFOM to normal rats caused no change in 
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FIGURE  1.  Rats  were given DFOM on days 0-7 (a), days 8-15 (b), days 11-18 (c), and days 
14-21 (d). The groups were: (&) GPSCH-CFA primed and treated with DFOM; (0) GPSCH- 
CFA primed and untreated; (I) unprimed and given DFOM. The duration of clinical symptoms 
is shown by the arrows for GPSeH-CFA-primed, treated (DFOM) and untreated (EAE) rats. 
The above patterns were repeated in both the incidence and severity of clinical 
impairment  observed in all groups of rats that  were dosed with DFOM (Table 
I).  Some  neurological  symptoms  were  seen  in  a  few  animals  subsequent  to 
withdrawal of the drug (groups A, D, and H), but these were generally mild and 
of reduced  duration.  In  addition,  the  clinically  affected rats  that  were  given 
DFOM showed rapid improvement during the course of treatment (compare G 
and H, Table I). 
The  impression  gained  from the  histological  analysis of sections of medulla 
and  spinal  cord  from  rats  treated  early  with  DFOM  was that  the  severity of 
inflammatory process was minimal  when compared with that recognized in the 
EAE-primed  controls  (Fig.  2).  Relatively few  lesions  were  observed,  and  the 
extent of cellular invasion was slight. Also, it was noted that sections from those 
animals that had already developed symptoms at the commencement of treatment 1536  ROLE  OF  IRON  IN  AUTOIMMUNITY 
TABLE  I 




Treatment  Days after sensitization 
DFOM  Days  12  14  16  18  20  22  24  28 
A  5  +  0-7  0  0  5  (1.0)  0  0  0  0  0 
B  5  0  5 (3.0)*  5 (3.5)  5  (2.0)  2 (0.5)  0  0  0 
1-4  2-4 
c  5  +  8-15  0  0  0  0  0  1 (1.5)  0  0 
D  5  3 (3.3)  3 (4.0)  4 (3.0)  2 (1.0)  2 (2.0)  1 (3.0)  0  1 (1.0) 
3-4  2-4  2-4  1-3 
E  5  +  11-18  0  0  0  0  0  0  1 (0.5)  0 
V  5  3 (1.0)  4 (2.0)  3 (1.7)  3 (1.0)  2 (1.0)  2 (2.0)  0  0 
1-3  1-3  1-3 
G  10  +  14-21  0  2 (1.5)  8 (1.4)  3 (1.0)  0  0  l (1.0)  0 
1-2  1-2 
H  10  14-21  0  2 (1.5)  7 (2.0)  6 (2.7)  2 (1.5)  3 (2.3)  2 (0.8)  !  0 
1-2  1-3  2-3  1-3  1-4  1-2 
* Osmotic pumps delivering  70 mg of DFOM per day were implanted into groups of five rats. The controls  were sham-operated.  The 
results  for days  14-21 are cumulated data for two groups of five animals:  the two animals  that relapsed  on day 24 were  from the 
same group. 
* The  results  are  given as:  number of clinically  affected  animals,  the  mean  clinical  score  for those  with neurological signs  (in 
parentheses)  and, on line below, the range of clinical scores where these varied. 
! These rats were examined daily from days 22-28, and showed symptoms only on days 24. 
showed evidence of numerous old lesions, with fibrin deposition but little cellular 
infiltration.  The  few  cells  that  were  present  had  the  general  appearance  of 
macrophages. 
Patterns of Lymphocyte Responsiveness.  The initial  hypothesis was that  DFOM 
may limit  the severity of EAE by removing free iron  necessary for generating 
hydroxyl  radicals.  However,  we  also  considered  the  possibility  that  the  drug 
might have direct effects on lymphocyte function. The analysis of this aspect was 
facilitated by the availability of the procoagulant assay for MBP-specific T  cells 
(Table  II).  Reactive  iymphocytes  can  be  detected  in  both  lymph  node  and 
peritoneal exudate populations from rats primed with GPSCH-CFA (Tables II 
and III). Effector function is apparently mediated by T  cells of the DTH/helper 
subset (Table III). 
PEC were taken at intervals from the rats that  had been examined clinically 
(Fig. 1, Table I) and were tested in the procoagulant assay. The level of response 
was depressed  for  PEC  sampled  from  1 to  3  d  after  the  cessation  of DFOM 
treatment  (groups A  and B, day  10; C and  D, day  16; E and  F, day 21; Table 
IV). This diminution in activity was least apparent for the rats that were clinically 
affected  when  drug  treatment  was  initiated  on  day  14,  though  evidence  of 
suppressed  lymphocyte function  was still  apparent  (groups  G  and  H,  day  21; 
Table IV).  However, by day 32 (Table IV),  PEC from all groups of rats given 
DFOM  showed levels of procoagulant  activity that  were comparable  to  those 
seen in the EAE controls. Thus, the capacity of lymphocytes to respond to MBP 
is completely restored within  11 d of the cessation of drug treatment (Table IV). 
This  may  reflect  that  GPSCH-CFA is  likely  to  persist as a  depot antigen  for 
several weeks after  injection.  Even  so,  recovery of lymphocyte responsiveness 
did not lead to the development of severe symptoms in any group, and  12 of the 
15 animals  that  were given  DFOM from day 8  onwards  remained  completely 
free of the disease after treatment (groups D, F, and H, Table I). BOWERN  ET  AL.  1537 
FIGURE 2.  The hematoxylin and eosin-stained sections are all from the medulla of rats killed 
29 d after priming with GPSCH-CFA. Those designated a and c are from untreated rats, while 
b and d are from animals  given  DFOM on days 14-21. The lesions shown  in a  and c are 
typical, while b and d illustrate  the most severe  inflammatory process that could be found in 
the DFOM-treated rats: the perivascular  cuff (b) is the only one observed in sections from this 
group, x  600 for a and b; X 150 for c and d. 
LNC  were  also  tested  from  other  rats  that  were  subjected  to  the  treatment 
schedules  used  for the clinical evaluation (groups A-F,  Table  I). These  animals 
were  killed  at  various  times  after  removal  of the  osmotic pumps.  The  patterns 
of response seen (Table V) were generally similar to those observed for the PEC 
populations (Table  IV). 
To determine  whether  DFOM  was inhibiting  macrophage or T  cell function, 
PEC from DFOM-treated  rats  were incubated  with  lipopolysaccharide  B  (LPS), 
which is  known to directly stimulate  procoagulant activity in macrophages (18). 
The  PEC  from  DFOM-treated  rats  responded  at  least  as  well  as  normal  PEC 
(Table VI). Also, the addition of LNC from untreated rats primed with GPSCH- 
CFA  18  d  previously  restored  the  capacity  of PEC  from  the  DFOM-treated 1538  ROLE  OF  IRON  IN  AUTOIMMUNITY 
TABLE  II 
Specificity of the MPCA Assay  for Peritoneal Exudate Populations 
Sensitization in vivo 
MPCA response (percent reduction in 
clotting time) on in vitro challenge 
with: 
Antigen  Day  MBP  OVA*  Nil 
GPSCH-CFA  7  23.4  2.5  3.7 
GPSCH-CFA  14  45.9  3.0  2.5 
GPSCH-CFA  21  25.2  3.5  3.6 
Nil  --  3.4  --  2.3 
* Ovalbumin. 
TABLE  III 
FACS Separation ofT Cells Responding in the MPCA Assay* 
Lymph node cells (LNC)  Percentage of  Reduction in clotting 
sorted for:  cells stained  time 
%  % 
W3/25 (helper]DTH)  25.3  35.4 + 2.1 
Unstained  --  <5.0 
Ox8 (cytotoxic/suppressor)  7.2  <5.0 
Unstained  --  38.2 ± 3.5 
Unseparated  --  48.0 + 4.4 
* The cells from rats sensitized with GPSCH-CFA  10 d previously were 
separated  into stained (fluorescent)  and  unstained populations on a 
FACS IV. They were then, together with unseparated cells that had not 
been passed through the FACS, stimulated with MBP in the presence of 
PEC (1:10  lymph node cells) from normal mice and supernates were 
assayed using the PU5 macrophage line. 
TABLE IV 
Levels of T Cell Responsiveness in Peritoneal Exudates 
Group* 
Treatment  Procoagnlant  activity on days:* 
Drug  Days  7  10  14  16  21  32 
A  Nil  0-7  --  12,0 ±1.7  --  --  23.4  ±  1.0  23.4  ±  2.0 
B  DFOM  0-7  --  3.3  ±  1.4!  --  --  23.0  ±  1.8  18.6 ±  2,4 
C  Nil  8-15  5.5 ±  1.3  --  --  21.6  ±  1.9  --  52.2  ±  2.1 
D  DFOM  8-15  5.5 ±  1.1  --  --  3,1  4-  1.1!  --  54.4  ±  6.2 
E  Nil  11-18  --  9.5±2.6  --  --  23.7±2.3  45.5±2.9 
F  DFOM  11-18  --  9.5±2.8  --  --  <1.0  49.8±2,7 
G  Nil  14-21  --  --  18.7 ±  1.5  --  24.1  ±  1.8  24.4  ±  2.7 
H  DFOM  14-21  --  --  19.2  ±  1.7  --  16.7 ±  3.5  t  20.8  ±  3.3 
*  These  are the same groups  as those shown  in Table  t  and  Fig.  1. 
* Mean  ±  SD for five animals; rats were injected  i.p. with thioglycollate 3  d  before  sampling. 
!  These  differences  are statistically significant (P <  0.05). 
animals to produce procoagulant factor on stimulation with MBP protein. Con- 
versely,  LNC  from  EAE/DFOM  rats  were  unable to  stimulate normal macro- 
phages in the presence of MBP.  The  defect resulting from DFOM  treatment is 
thus in the lymphocyte rather than the macrophage population. BOWERN  ET  AL. 
TABLE  V 
MPCA-promoting Activity of Lymph Node Cells 
Days given  Day of  Reduction in 
DFOM  sampling  clotting time* 
% 
0-7  13  9.7 
Nil  13  39.0 
8-15  31  51.1 
Nil  31  33.7 
11-18  18  14.0 
Nil  18  28.7 
11-18  35  49.8 
Nil  35  35.8 
* Supernates from  cultures with MBP were assayed using the PU5 celt 
line. 
TABLE  VI 
Restoration  of PEC Reactivity by Addition of EAE-sensitized  LNC 
PEC*  LNC  MBP  LPS 
Normal  None  4.1 
EAE/DFOM (days 11-18)  None  1.0 
EAE/DFOM (days 11-18)  EAE LNC  36.5 
EAE/DFOM (days 11-18)  Normal LNC  4.5 
EAE (day 18)  None  36.0 
Normal  EAE LNC  38.7 
None  EAE LNC  3.9 
Normal  DFOM/EAE LNC  2.4 
None  DFOM/EAE LNC  1.5 
39.3 
42.3 
* PEC were tested for procoagulant activity by incubation with antigen 
(MBP, 5 #g/ml or LPS, 0.01  t~g/ml) for  16 h. LNC from EAE (day 18 
PI), DFOM/EAE (DFOM days 11-18) or normal rats were added at 3 
x  105/108 PEC, the optimum ratio for stimulation (unpublished results). 
Results are expressed as a reduction in clotting time of normal plasma. 
TAI~LE  VII 
Effect of DFOM and FeCl3 on T Cell Proliferation 
1539 
Stimulation index* 
Lymph node  MBP + 
MBP +  MBP +  cells  Con A  MBP  (DFOM + 
DFOM  FeCIs)  FeCls 
EAE day 10  4.0  2.9  1.0  2.3  2.3 
Normal  6.4  < 1  <1  <1  1.1 
* Results are expressed as a stimulation index relative to counts for unstimulated control 
cultures. 
A  further experiment was  done in  vitro to  establish  whether the  effect of 
DFOM was indeed mediated via the removal of loosely bound iron. Lymph node 1540  ROLE  OF  IRON  IN  AUTOIMMUNITY 
cells from EAE-primed rats  were incubated in  vitro with  MBP.  The resultant 
proliferative response was completely inhibited by incorporating DFOM in the 
medium (Table VII). However, the inhibitory effect of DFOM was substantially 
reversed when the drug was saturated with Fe  ~+ before adding it to the culture, 
indicating  that  DFOM  suppresses  lymphocyte responses  by  chelating  loosely 
bound iron. 
Discussion 
Our results show that the severity of EAE is greatly diminished in rats given 
the iron-chelating agent DFOM. The effects range from complete prevention of 
the development of neurological symptoms to more rapid recovery in rats that 
are already clinically affected. The clinical pattern is broadly reflected in  the 
extent of histopathological changes. Recovery of lymphocyte responsiveness after 
the cessation of therapy does not lead to the development of severe disease. 
The protective effect of DFOM in EAE is also directly related to the level of 
responsiveness for  lymphocytes of the  DTH/helper  subset,  taken  from both 
lymph nodes and the peritoneal cavity. The most likely reason for the reduction 
in the severity of the disease is thus that DFOM is a potent immunosuppressive 
agent for DTH effector T  cells (6). The finding that DFOM suppresses lympho- 
cyte proliferation in vitro and the fact that this is reversed by addition of FeCls 
indicates that the depressive effect may operate via removal of loosely bound 
iron; further experiments are in progress so that a definitive conclusion of this 
type can  be  made.  Iron  is  also  thought  to  be  necessary for  other aspects  of 
lymphocyte function,  including  recirculation  and  homing  (20).  Dietary  iron 
deficiency is associated (in various antigen systems) with reduced delayed hyper- 
sensitivity (20), failure of sensitized lymphocytes to bind to target cells (22), and 
decreased DNA synthesis (23). 
Incubation with DFOM appeared to have little effect on macrophages in vitro, 
in that it did not inhibit the production of procoagulant in response to endotoxin 
stimulation or phagocytosis of zymosan particles (unpublished results) at drug 
concentrations that  depress  lymphocyte proliferation.  However,  macrophages 
are well supplied with lysosomal iron (24). Thus, the relatively short assay time 
and concentrations of DFOM  used may not have been sufficient to cause any 
inhibition of function. 
Apparently, DFOM is acting primarily on lymphocytes. The observation that 
a  more rapid resolution of the disease was seen in rats that were treated after 
the development of symptoms indicates that these effects may operate in the site 
of pathology.  Decreased production  of procoagulant  in  inflammatory lesions 
might be expected to reduce the deposition of fibrin in white matter in  EAE 
(25).  Chelation and removal of free iron from sites of inflammation may also 
prevent free radical-induced lipid peroxidation and production of chemotactic 
factors resulting from tissue damage. An excess of free iron in the CNS is known 
to contribute directly to such processes, and to the development of gliosis (26). 
It is of interest that iron deposits in the form of hemosiderin, which can be 
mobilized by DFOM (27), have been found in multiple sclerosis plaques (28). In 
fact, in one study, iron levels in such plaques were found to be approximately 
five times the level  found in  normal  nervous tissue  (20).  There is thus some BOWERN ET  AL.  1541 
reason to think that, both from the aspect of removing iron from the brain and 
of reducing lymphocyte stimulation,  DFOM might merit a trial as a therapeutic 
agent in multiple sclerosis. The drug is relatively nontoxic, having been used for 
many years to treat both iron overload and iron poisoning (30,  31) and,  more 
recently, the tissue damage of long-term hemodialysis (32). Our in vitro results 
also suggest that  drugs that  remove free iron  may be of general  value as mild 
immunosuppressive agents to inhibit autoreactive, or rejection processes involv- 
ing lymphocytes of the DTH/helper subset. 
Summary 
Lewis  rats  that  are  primed  with  guinea  pig  spinal  cord  homogenized  in 
complete Freund's adjuvant (GPSCH-CFA) develop overt symptoms of experi- 
mental  allergic  encephalomyelitis  (EAE).  Treatment  with  the  iron-chelating 
agent, desferrioxamine B mesylate (DFOM), at various times before the onset of 
EAE, dramatically  suppressed both the severity and duration  of disease.  When 
DFOM  was administered  to  rats  soon  after  the  development  of neurological 
signs, a rapid recovery occurred, though mild, transient symptoms could be seen 
1 wk after withdrawal of the drug. Treatment with DFOM was always accom- 
panied by a diminution  of T  cell responsiveness on the part of the delayed-type 
hypersensitivity/helper  subset and,  on  histological  examination,  an  absence of 
inflammatory cells from lesions. Iron is believed to influence both the migration 
and function of immune effector cells. It can also act as a catalyst in the formation 
of free radicals,  which are highly toxic agents causing tissue damage in sites of 
inflammation.  The mechanisms underlying the effect of DFOM on the severity 
of EAE,  and  the  possible implications  for  treatment  of multiple  sclerosis are 
discussed. 
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